Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2018 5
2019 3
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.
Souza CP, Rosychuk RAW, Contreras ET, Schissler JR, Simpson AC. Souza CP, et al. Vet Dermatol. 2018 Dec;29(6):489-e164. doi: 10.1111/vde.12682. Epub 2018 Aug 23. Vet Dermatol. 2018. PMID: 30141223
BACKGROUND: Lokivetmab neutralizes IL-31, a cytokine that plays an important role in the pathogenesis of atopic dermatitis (AD) in dogs. ...There were no significant associations between treatment success and age of onset of clinical signs, disease chronicity, lokivetma
BACKGROUND: Lokivetmab neutralizes IL-31, a cytokine that plays an important role in the pathogenesis of atopic dermatitis (AD) in do …
A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
Moyaert H, Van Brussel L, Borowski S, Escalada M, Mahabir SP, Walters RR, Stegemann MR. Moyaert H, et al. Vet Dermatol. 2017 Dec;28(6):593-e145. doi: 10.1111/vde.12478. Epub 2017 Sep 14. Vet Dermatol. 2017. PMID: 28906040 Clinical Trial.
BACKGROUND: Lokivetmab is an injectable anti-canine-IL-31 monoclonal antibody to treat clinical manifestations of atopic dermatitis (AD) in dogs. ...RESULTS: Lokivetmab was noninferior to ciclosporin for pruritus reduction on Day 28 (51.90% versus 43.72%). For Day 2 …
BACKGROUND: Lokivetmab is an injectable anti-canine-IL-31 monoclonal antibody to treat clinical manifestations of atopic dermatitis ( …
Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis.
Meichner K, Kiupel M, Kasantikul T, Rakich P, Banovic F. Meichner K, et al. Vet Dermatol. 2019 Feb;30(1):73-e22. doi: 10.1111/vde.12702. Epub 2018 Nov 26. Vet Dermatol. 2019. PMID: 30479052
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's pruritus resolved within seven days and was maintained in remission over 15 months with once monthly lokivetmab injections; the skin …
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's …
A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
Michels GM, Ramsey DS, Walsh KF, Martinon OM, Mahabir SP, Hoevers JD, Walters RR, Dunham SA. Michels GM, et al. Vet Dermatol. 2016 Dec;27(6):478-e129. doi: 10.1111/vde.12376. Epub 2016 Sep 19. Vet Dermatol. 2016. PMID: 27647569 Clinical Trial.
HYPOTHESIS/OBJECTIVES: The objective was to describe lokivetmab dose response in a randomized, double blind, placebo-controlled trial. ...METHODS: Dogs were randomized to treatment with lokivetmab (0.125, 0.5 or 2.0 mg/kg) or placebo administered subcutaneously once …
HYPOTHESIS/OBJECTIVES: The objective was to describe lokivetmab dose response in a randomized, double blind, placebo-controlled trial …
Proactive maintenance therapy of canine atopic dermatitis with the anti-IL-31 lokivetmab. Can a monoclonal antibody blocking a single cytokine prevent allergy flares?
Tamamoto-Mochizuki C, Paps JS, Olivry T. Tamamoto-Mochizuki C, et al. Vet Dermatol. 2019 Jan 23. doi: 10.1111/vde.12715. Online ahead of print. Vet Dermatol. 2019. PMID: 30672050
OBJECTIVES: We wished to determine if the proactive administration of the anti-IL-31 lokivetmab would prevent or delay flares of canine AD. ...In dogs with spontaneous AD, the median TTF after lokivetmab proactive therapy was 63 days. One-fourth of dogs did not exhi …
OBJECTIVES: We wished to determine if the proactive administration of the anti-IL-31 lokivetmab would prevent or delay flares of cani …
A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis.
Michels GM, Walsh KF, Kryda KA, Mahabir SP, Walters RR, Hoevers JD, Martinon OM. Michels GM, et al. Vet Dermatol. 2016 Dec;27(6):505-e136. doi: 10.1111/vde.12364. Epub 2016 Sep 19. Vet Dermatol. 2016. PMID: 27647513 Clinical Trial.
METHODS: Dogs were randomized at a 2:1 ratio to receive either lokivetmab (1.0-3.3 mg/kg) or placebo administered subcutaneously on days 0 and 28. ...Discomfort at administration occurred in 5.1% of dogs and was similar in frequency and severity between lokivetmab- …
METHODS: Dogs were randomized at a 2:1 ratio to receive either lokivetmab (1.0-3.3 mg/kg) or placebo administered subcutaneously on d …
The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis.
Szczepanik M, Wilkołek P, Gołyński M, Sitkowski W, Taszkun I, Toczek W. Szczepanik M, et al. Vet Dermatol. 2019 Aug;30(4):330-e93. doi: 10.1111/vde.12758. Epub 2019 May 14. Vet Dermatol. 2019. PMID: 31090122
HYPOTHESIS: This study aimed to assess changes in transepidermal water loss (TEWL) during 12 weeks of treatment with lokivetmab and its correlation with the CADESI-04 and the severity of pruritus. ...METHODS AND MATERIALS: The animals were administered lokivetmab th …
HYPOTHESIS: This study aimed to assess changes in transepidermal water loss (TEWL) during 12 weeks of treatment with lokivetmab and i …
Atopic dermatitis in cats and dogs: a difficult disease for animals and owners.
Gedon NKY, Mueller RS. Gedon NKY, et al. Clin Transl Allergy. 2018 Oct 5;8:41. doi: 10.1186/s13601-018-0228-5. eCollection 2018. Clin Transl Allergy. 2018. PMID: 30323921 Free PMC article. Review.
[New drugs for small animals in 2017].
Emmerich IU. Emmerich IU. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2018 Apr;46(2):99-104. doi: 10.15654/TPK-180334. Epub 2018 May 4. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2018. PMID: 29727897 German.
In 2017 the active pharmaceutical ingredient Lokivetmab (Cytopoint®), a caninized anti-canine Interleukin 31 monoclonal antibody, was released on the German market for small animals. ...
In 2017 the active pharmaceutical ingredient Lokivetmab (Cytopoint®), a caninized anti-canine Interleukin 31 monoclonal antibody, was …
12 results
Jump to page
Feedback